Sanofi (NASDAQ:SNY) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Sanofi (NASDAQ:SNY) have been assigned a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $62.00.

A number of research firms have recently commented on SNY. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Sanofi in a research report on Tuesday, August 5th. Finally, Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd.

Sanofi Trading Up 1.5%

NASDAQ SNY opened at $51.35 on Monday. The company’s fifty day simple moving average is $48.62 and its 200-day simple moving average is $51.73. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock has a market cap of $126.09 billion, a P/E ratio of 12.34, a PEG ratio of 1.21 and a beta of 0.48.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the previous year, the firm posted $1.73 earnings per share. The company’s revenue for the quarter was down 7.0% on a year-over-year basis. Equities research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Trading of Sanofi

A number of hedge funds have recently made changes to their positions in the stock. Cardinal Capital Management grew its position in shares of Sanofi by 0.3% during the first quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock worth $3,827,000 after buying an additional 199 shares in the last quarter. Gradient Investments LLC boosted its holdings in Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock worth $542,000 after purchasing an additional 200 shares during the period. Perigon Wealth Management LLC boosted its holdings in Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock worth $367,000 after purchasing an additional 201 shares during the period. Capital Analysts LLC boosted its holdings in Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after purchasing an additional 204 shares during the period. Finally, Thomasville National Bank boosted its holdings in Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after purchasing an additional 211 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.